CytoPherx is a medical device company offering a proprietary selective cytopheresis sytem for inflammation-based diseases and conditions.
CytoPherx (formerly Nephrion) clinical stage medical device company addressing inflammation-based diseases and conditions. The company’s products are custom configurations of a proprietary selective cytopheresis-based inflammation modulating system.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Jun 17, 2010 | Series B | $11.70M | 1 | Diamond Capital Management | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
Diamond Capital Management | Yes | Series B |